| HOME >> MEDICINE >> TECHNOLOGY |
Soarian Financials 65
Siemens molecular diagnostic assays 66
Integrated diagnostics 67
The customer's perspective 70
2009 Molecular Summit, Philadelphia, USA 2009 71
Susquehanna Health 73
Conclusions 73
Chapter 5 GE Healthcare's early health model 75
Summary 75
Introduction 76
Early healthcare 76
"Healthymagination" 78
Digital imaging 79
Omnyx Integrated Digital Pathology solution (IDP) 80
GE and Eli Lilly 81
GE and VirtualScopics 82
GE and Merck 82
GE acquires Orbitech 83
The PredictAD Project 83
GE and Clarient 84
GE and ONI Medical Systems 84
Conclusions 84
Chapter 6 Other imaging companies entering the IVD market 86
Summary 86
Introduction 87
Philips Healthcare and Biomerieux 87
HistoRx 89
Bayer Schering Pharma 89
Imaging Diagnostic Systems 91
Given Imaging 92
AION Diagnostics 93
Chapter 7 Development Perspectives and Market Outlook 94
Summary 94
Introduction 95
Integrated diagnostics 96
Emerging developments 98
Breast cancer biomarkers 98
Breast cancer predisposition 100
Detection of breast cancer 101
Diagnosis of breast cancer 102
Metastatic breast cancer 104
Response to therapy 105
Prognosis 106
Alzheimer's disease 107
Prediction of AD 108
Detection of AD 110
Imaged-based biomarkers in AD 112
Market forecasts 116
Biomarkers and risks 118
Driving changes 119
Bibliography 121
Table of figures
Figure 1: The drivers shaping integration in medical diagnostics 18
Figure 2: Biomarkers with utility in the detection, diagnosis and treatment of breast cancer 22
Figure 3: Sources of biomarkers reported with utility in the detection, diagnosis and treatment of breast cancer 23
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |